Disclaimer

This website is not an offer to sell or a solicitation of an offer to buy securities. Any offer is made only through the Private Placement Memorandum, to verified accredited investors under Rule 506(c) of Regulation D.

The securities have not been registered under the Securities Act of 1933 and are offered in reliance on Rule 506(c) of Regulation D. Neither the SEC nor any state securities regulator has approved or disapproved the securities or passed upon the accuracy or adequacy of the offering materials.

Forward-looking statements describe development plans and potential applications, rather than assured outcomes. Clinical results, regulatory authorizations, commercialization, and financing remain subject to risks and uncertainties. Intellectual property rights vary by agreement, jurisdiction, and filing status. Patents issued may be invalidated. Patents pending may not be issued. The company may be found to infringe on patents of others. Regulatory statuses may be challenged. Clinical data is all early stage and may not hold up in large-scale controlled studies. The company lacks the resources to complete all proposed product developments. The company is underinsured and understaffed for the work it is doing. Financial information is subject to adjustment after external review and audits.

Forward-looking statements reflect current expectations and involve uncertainties. Actual results may differ materially.

Investing in Lionheart Health involves a high degree of risk, including loss of the entire investment, limited liquidity, dilution, additional financing needs, competition, intellectual-property risks, and clinical or regulatory uncertainty.

The securities are not FDIC insured, may lose value, and have no bank guarantee.